1. [CASE 1 — QUESTION 1]
A 58-year-old woman presents with severe epigastric pain radiating to the back, vomiting, and a lipase of 1,800 U/L. Ultrasound shows cholelithiasis without ductal dilation. She is tachycardic to 118 bpm, with a hematocrit of 49% and a urine output of 0.3 mL/kg/hour, consistent with hypovolemia from third-space losses. The team is initiating fluid resuscitation. Which crystalloid is preferred, and why?
A) 0.9% normal saline, because its higher chloride content accelerates clearance of inflammatory mediators
B) 5% dextrose in water, because free-water replacement best corrects third-space losses
C) Lactated Ringer's, because it is buffered and avoids the hyperchloremic metabolic acidosis associated with large-volume saline, which is linked to greater systemic inflammatory response activation
D) 0.45% half-normal saline, because a hypotonic fluid limits pancreatic interstitial edema
E) 3% hypertonic saline, because raising osmolality withdraws fluid from the inflamed pancreatic bed
ANSWER: C
Rationale:
Lactated Ringer's (LR) is the preferred resuscitation fluid in acute pancreatitis. LR is buffered—lactate is metabolized to bicarbonate—and avoids the hyperchloremic metabolic acidosis produced by large-volume 0.9% saline, an acidosis associated with greater systemic inflammatory response syndrome (SIRS — a generalized inflammatory state) activation; trial data favor LR for reducing progression to more severe disease.
Option A: Option A is incorrect: the high chloride load of saline promotes acidosis rather than mediator clearance.
Option B: Option B is incorrect: dextrose in water is a free-water solution that does not provide the isotonic volume expansion needed.
Option D: Option D is incorrect: hypotonic half-normal saline is not an appropriate resuscitation fluid and does not limit pancreatic edema.
Option E: Option E is incorrect: hypertonic saline is not standard resuscitation and is not supported here.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. She is now hemodynamically stabilized but is predicted to have a severe course and will not tolerate oral intake for several days. A nasogastric tube is in place and the gut is functional. Which nutritional strategy is preferred?
A) Early enteral nutrition, because it maintains gut mucosal integrity, limits bacterial translocation, and reduces infectious complications compared with parenteral nutrition
B) Total parenteral nutrition, because complete bowel rest halts pancreatic enzyme secretion
C) Prolonged nil-per-os with intravenous fluids alone for at least 7 days
D) Clear liquids advanced slowly to solids, because the stepwise progression lowers complications
E) Peripheral parenteral nutrition as the preferred first-line route
ANSWER: A
Rationale:
Early enteral nutrition is preferred in acute pancreatitis when the gut is functional. It preserves gut mucosal integrity, limits bacterial translocation, and reduces infectious complications relative to parenteral nutrition; nasogastric and nasojejunal routes are comparable.
Option B: Option B is incorrect: total parenteral nutrition is reserved for when enteral access cannot be established or is not tolerated, and it does not improve outcomes here.
Option C: Option C is incorrect: prolonged starvation is harmful and not protective.
Option D: Option D is incorrect: when oral intake resumes, low-fat soft solids are appropriate, and the clear-liquid-to-solid progression does not reduce complications and prolongs stay; it is not the current strategy for a patient who cannot yet eat.
Option E: Option E is incorrect: peripheral parenteral nutrition is still a parenteral fallback, not the preferred route.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. On day 9 she develops worsening fever and leukocytosis. CT shows pancreatic necrosis without gas, and no infection has been documented. Applying antibiotic stewardship principles, what is the most appropriate next step?
A) Begin empiric broad-spectrum antibiotics immediately, because clinical deterioration establishes infected necrosis
B) Begin prophylactic antibiotics and continue them until the necrosis resolves regardless of cultures
C) Start empiric antifungal therapy, since fungal infection is the most likely cause of deterioration
D) Withhold antibiotics permanently, because they have no role at any point in necrotizing pancreatitis
E) Defer empiric antibiotics and pursue confirmation of infection—such as fine-needle aspiration when imaging cannot distinguish infected from sterile necrosis and the result will change management
ANSWER: E
Rationale:
Clinical deterioration in necrotizing pancreatitis often reflects sterile systemic inflammation rather than infection, and antibiotics are validated only for confirmed infected necrosis or cholangitis. The appropriate step is to seek confirmation—fine-needle aspiration is indicated when imaging cannot distinguish infected from sterile necrosis and the result will change management—rather than to start antibiotics reflexively.
Option A: Option A is incorrect: deterioration alone does not establish infection.
Option B: Option B is incorrect: prophylaxis in sterile necrosis confers no benefit and adds resistance and Clostridioides difficile risk.
Option C: Option C is incorrect: empiric antifungals are not warranted without demonstrated fungal involvement.
Option D: Option D overstates the principle: antibiotics are appropriate once infection is confirmed.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. Fine-needle aspiration confirms infected pancreatic necrosis with a gram-negative organism, and a walled-off necrotic collection is now present. She is started on a carbapenem. Which statement best describes definitive management of the infected walled-off necrosis?
A) Antibiotic therapy alone is curative, and no drainage or debridement is needed
B) Definitive management is drainage or debridement—typically a step-up approach beginning with endoscopic or percutaneous drainage—with the tissue-penetrating antibiotic serving as adjunctive therapy
C) Immediate open necrosectomy is the required first intervention before any antibiotics
D) The carbapenem should be stopped now that a collection is identified, since antibiotics worsen walled-off necrosis
E) A bile acid sequestrant should be added to chemically dissolve the necrotic collection
ANSWER: B
Rationale:
Definitive management of infected walled-off pancreatic necrosis is drainage or debridement, classically via a step-up approach that begins with endoscopic or percutaneous drainage and escalates only if needed; tissue-penetrating antibiotics such as carbapenems are adjunctive.
Option A: Option A is incorrect: antibiotics alone do not definitively treat infected walled-off necrosis.
Option C: Option C is incorrect: immediate open necrosectomy is not the required first step; the step-up approach is preferred and reduces morbidity.
Option D: Option D is incorrect: the antibiotic is appropriately continued as adjunctive therapy for the confirmed infection.
Option E: Option E is incorrect: bile acid sequestrants have no role in dissolving necrotic collections.
5. [CASE 2 — QUESTION 1]
A 54-year-old man with a 20-year history of alcohol-related chronic pancreatitis reports bulky, greasy, foul-smelling stools, a 9-kg weight loss, and a low fecal elastase. Serum 25-hydroxyvitamin D is low. Which intervention is the definitive pharmacological treatment for his exocrine pancreatic insufficiency, and how is it dosed?
A) Oral amylase supplements dosed to carbohydrate intake, since carbohydrate maldigestion drives the steatorrhea
B) A proton pump inhibitor alone, since raising gastric pH corrects fat malabsorption without enzymes
C) An antimotility agent dosed to stool frequency, since slowing transit resolves the malabsorption
D) Pancreatic enzyme replacement therapy dosed by lipase units (about 40,000–50,000 units per main meal), because lipase is the critical component and fat malabsorption drives the morbidity
E) A bile acid sequestrant dosed to fat intake, since binding luminal fat improves absorption
ANSWER: D
Rationale:
Pancreatic enzyme replacement therapy (PERT) is the definitive treatment for exocrine pancreatic insufficiency, and it is dosed by lipase units (approximately 40,000–50,000 lipase units per main meal, half that per snack) because lipase is the critical component and fat maldigestion produces the greatest morbidity, including the steatorrhea and fat-soluble vitamin deficiency seen here.
Option A: Option A is incorrect: amylase is not the dose-defining component, and carbohydrate maldigestion is not the driver of steatorrhea.
Option B: Option B is incorrect: a proton pump inhibitor is an adjunct to enzymes, not a replacement for them.
Option C: Option C is incorrect: an antimotility agent does not correct the underlying enzyme deficiency.
Option E: Option E is incorrect: a bile acid sequestrant binds bile acids and would worsen fat absorption.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. He is started on enteric-coated enzyme microspheres but reports taking the full dose 30 minutes before each meal. His steatorrhea persists. What correction to administration is most appropriate?
A) Take the enzymes during the meal, splitting the dose across a large meal to improve mixing with the food bolus
B) Take the enzymes 60 minutes after the meal to allow gastric emptying first
C) Crush the microspheres into a hot beverage taken before eating to speed dissolution
D) Switch to a non-enteric-coated preparation taken on an empty stomach
E) Take the entire daily dose once at bedtime, independent of meals
ANSWER: A
Rationale:
Enzymes must be taken during the meal so the microspheres mix with the food bolus, empty with the chyme, and release in synchrony with nutrient delivery to the duodenum; for large meals, splitting the dose improves mixing.
Option B: Option B is incorrect: dosing after the meal misses the bolus and gives poor mixing.
Option C: Option C is incorrect: hot liquids and crushing disrupt the enteric coating and inactivate the enzymes.
Option D: Option D is incorrect: non-enteric-coated products are more vulnerable to gastric acid, and empty-stomach dosing desynchronizes release.
Option E: Option E is incorrect: bedtime-only dosing is unrelated to meals and will not aid digestion.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. After timing is corrected and the lipase dose is increased toward 80,000 units per meal, he still has steatorrhea, and testing documents a persistently low duodenal pH. What is the best next step?
A) Discontinue the enzymes, since persistent steatorrhea proves intrinsic ineffectiveness
B) Reduce the lipase dose to limit the risk of fibrosing colonopathy
C) Add a proton pump inhibitor to raise duodenal pH above the enteric-coating dissolution threshold, so enzymes are released and not acid-inactivated
D) Add a bile acid sequestrant to bind the malabsorbed fat
E) Switch to a large-particle, non-enteric-coated enzyme preparation
ANSWER: C
Rationale:
With dosing, timing, and formulation optimized and a documented low duodenal pH, acid is the limiting factor: the enteric coating will not dissolve and released enzymes are denatured. Adding a proton pump inhibitor raises duodenal pH above the dissolution threshold and restores efficacy.
Option A: Option A is incorrect: the enzymes are not intrinsically failing; the acidic duodenal environment must be corrected.
Option B: Option B is incorrect: lowering the dose would worsen steatorrhea, and the dose is within the standard range.
Option D: Option D is incorrect: a bile acid sequestrant would worsen fat absorption.
Option E: Option E is incorrect: large-particle non-enteric-coated preparations are less bioavailable and more acid-vulnerable.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. His steatorrhea improves on the proton pump inhibitor, but he now has persistent neuropathic-type abdominal pain on acetaminophen, and he continues to drink alcohol. Which approach best addresses both his pain and his long-term disease trajectory?
A) Initiate a scheduled long-acting opioid as first-line therapy and take no action on alcohol use
B) Begin a chronic oral corticosteroid taper as the primary analgesic strategy
C) Recommend immediate total pancreatectomy to eliminate the pain source
D) Withhold all analgesia until he achieves alcohol abstinence
E) Add pregabalin as an opioid-sparing adjunct that modulates central pain sensitization, and emphasize alcohol cessation as the single most impactful intervention on disease progression, while monitoring fat-soluble vitamins
ANSWER: E
Rationale:
For chronic pancreatitis pain with active alcohol use disorder, pregabalin (an alpha-2-delta calcium channel subunit modulator) gives modest, opioid-sparing benefit, and alcohol cessation is the single most impactful intervention on disease progression; ongoing fat-soluble vitamin monitoring remains essential in established exocrine insufficiency.
Option A: Option A is incorrect: making a long-acting opioid first-line ignores the heightened dependence risk and the opioid-sparing goal.
Option B: Option B is incorrect: chronic corticosteroids are not an established analgesic strategy for chronic pancreatitis and carry substantial harm.
Option C: Option C is incorrect: total pancreatectomy is not an appropriate first response to inadequately trialed medical management.
Option D: Option D is incorrect: withholding analgesia until abstinence is neither humane nor effective.
9. [CASE 3 — QUESTION 1]
A 62-year-old man with a metastatic midgut neuroendocrine tumor and hepatic metastases has episodic flushing, secretory diarrhea, and intermittent wheezing. Urinary 5-hydroxyindoleacetic acid is elevated. Which pharmacological therapy is first-line to control his carcinoid syndrome symptoms, and by what mechanism?
A) A peripheral serotonin 5-HT3 receptor antagonist, which blocks the receptors mediating flushing and diarrhea
B) Octreotide LAR, a somatostatin analogue that agonizes somatostatin receptors (notably SSTR2/SSTR5) and suppresses secretion of serotonin and other vasoactive mediators
C) A nonselective beta-blocker, which blunts the catecholamine surge responsible for the symptoms
D) An H1 antihistamine, which blocks the histamine-mediated component as primary therapy
E) A proton pump inhibitor, which reduces the acid-driven diarrhea of carcinoid syndrome
ANSWER: B
Rationale:
Somatostatin analogues such as octreotide LAR are first-line for carcinoid syndrome; by agonizing somatostatin receptors (notably SSTR2/SSTR5), they suppress secretion of serotonin and other vasoactive mediators, controlling flushing, diarrhea, and bronchospasm.
Option A: Option A is incorrect: a 5-HT3 antagonist treats nausea/vomiting and does not control the broad mediator-driven syndrome.
Option C: Option C is incorrect: the symptoms are mediated by serotonin and other vasoactive substances, not catecholamines, so a beta-blocker is not the therapy.
Option D: Option D is incorrect: an H1 antihistamine addresses only a minor component and is not first-line.
Option E: Option E is incorrect: carcinoid diarrhea is mediator-driven secretory diarrhea, not acid-driven.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. His flushing and diarrhea improve on octreotide LAR. He asks whether the drug does anything beyond symptom relief. Which statement best describes the additional benefit?
A) It provides no disease-modifying benefit and is purely palliative for symptoms
B) It cures the tumor by inducing complete apoptosis of all neuroendocrine cells
C) It stimulates an immune response that eradicates the hepatic metastases
D) Through SSTR2-mediated cell-cycle arrest, pro-apoptotic, and anti-angiogenic effects, it exerts an antiproliferative action that prolongs time to tumor progression
E) It accelerates hepatic metabolism of circulating serotonin, shrinking the tumor directly
ANSWER: D
Rationale:
Beyond suppressing secretion, somatostatin analogues exert antiproliferative effects through SSTR2-mediated cell-cycle arrest, promotion of apoptosis, and inhibition of angiogenic growth factor secretion, prolonging time to tumor progression in midgut neuroendocrine tumors.
Option A: Option A is incorrect: octreotide is not purely palliative; it has an established antiproliferative effect.
Option B: Option B overstates the effect: it delays progression but does not cure by total apoptosis.
Option C: Option C is incorrect: the effect is receptor-mediated, not immune-stimulating.
Option E: Option E is incorrect: the benefit is receptor-mediated antiproliferation, not acceleration of hepatic serotonin metabolism.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. He is scheduled for hepatic artery embolization of the metastases. The interventional team asks how to prevent a life-threatening intraprocedural surge of flushing, bronchospasm, and hemodynamic collapse. What is the standard prophylaxis?
A) High-dose octreotide given before the procedure and continued as an infusion during it, to prevent carcinoid crisis
B) A prophylactic epinephrine infusion started before the procedure
C) Intravenous hydrocortisone and diphenhydramine as the primary preventive regimen
D) A beta-blocker infusion to prevent catecholamine-driven hemodynamic surges
E) Withholding the somatostatin analogue on the day of the procedure to avoid interactions
ANSWER: A
Rationale:
Patients with carcinoid syndrome undergoing surgery, anesthesia, or hepatic artery embolization are at risk for carcinoid crisis—a life-threatening surge of vasoactive mediators. High-dose octreotide (for example, a 500-microgram intravenous bolus before the procedure followed by a 50–100 microgram/hour infusion) is the standard prophylaxis, and octreotide is also the treatment of choice for an established crisis.
Option B: Option B is incorrect: epinephrine can worsen mediator release and instability.
Option C: Option C is incorrect: corticosteroids and antihistamines do not block the broad range of vasoactive mediators.
Option D: Option D is incorrect: the crisis is mediator-driven, not catecholamine-driven, so a beta-blocker is not preventive.
Option E: Option E is incorrect: somatostatin analogue therapy should be continued and intensified perioperatively, not withheld.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. Eighteen months later, imaging shows clear progression of the hepatic metastases despite continued octreotide. Which statement best describes the appropriate next-line systemic options for progressive, well-differentiated gastroenteropancreatic neuroendocrine tumor?
A) No further systemic therapy exists; only best supportive care remains
B) Cytotoxic anthracycline chemotherapy is the established first escalation for well-differentiated midgut tumors
C) Options reserved for progression on a somatostatin analogue include everolimus (an mTOR inhibitor), sunitinib (a multi-targeted tyrosine kinase inhibitor, active in pancreatic NETs), and peptide receptor radionuclide therapy with lutetium-177-DOTATATE, which binds SSTR2 on tumor cells
D) The octreotide should simply be stopped, as it is now accelerating tumor growth
E) High-dose corticosteroids are the standard next-line therapy for progression
ANSWER: C
Rationale:
For progressive or refractory gastroenteropancreatic neuroendocrine tumors after a somatostatin analogue, additional systemic options include everolimus (an mTOR — mechanistic target of rapamycin — inhibitor), sunitinib (a multi-targeted tyrosine kinase inhibitor active in pancreatic NETs), and peptide receptor radionuclide therapy (PRRT) with lutetium-177-DOTATATE, which binds SSTR2 on tumor cells to deliver targeted radiation; these are reserved for progression.
Option A: Option A is incorrect: effective next-line options exist.
Option B: Option B is incorrect: anthracycline chemotherapy is not the established escalation for well-differentiated midgut tumors.
Option D: Option D is incorrect: somatostatin analogues do not accelerate growth; they are often continued for symptom control.
Option E: Option E is incorrect: high-dose corticosteroids are not standard next-line therapy.
13. [CASE 4 — QUESTION 1]
A 59-year-old woman has recurrent episodes of confusion and diaphoresis relieved by eating. A supervised fast reproduces neuroglycopenic symptoms with a glucose of 38 mg/dL, an inappropriately elevated insulin and C-peptide, and a negative sulfonylurea screen. Imaging localizes a solitary pancreatic lesion that is deemed inoperable due to comorbidity. What is the principal pharmacological goal of therapy?
A) To antagonize peripheral insulin receptors so that circulating insulin cannot act
B) To accelerate hepatic gluconeogenesis with a glucocorticoid as primary therapy
C) To replace deficient glucagon on a scheduled basis as the mainstay
D) To increase insulin secretion so beta-cell stores are exhausted
E) To suppress autonomous insulin secretion from the tumor and thereby prevent hypoglycemia
ANSWER: E
Rationale:
Insulinoma causes hypoglycemia through autonomous, glucose-independent insulin secretion; when surgery is not possible, the principal pharmacological goal is to suppress insulin release and prevent hypoglycemia.
Option A: Option A is incorrect: peripheral insulin-receptor antagonism is not an available or standard strategy.
Option B: Option B is incorrect: a glucocorticoid is not the primary therapy for insulinoma-related hypoglycemia.
Option C: Option C is incorrect: scheduled glucagon replacement is not the mainstay of management.
Option D: Option D is incorrect: increasing insulin secretion would worsen hypoglycemia.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. Diazoxide is selected. Which mechanism explains how it suppresses insulin secretion at the beta cell?
A) It blocks ATP-sensitive potassium channels, depolarizing the beta cell
B) It opens ATP-sensitive potassium channels, hyperpolarizing the beta cell so voltage-gated calcium channels stay closed and calcium-triggered insulin exocytosis is suppressed
C) It directly blocks the insulin secretory vesicle docking proteins
D) It inhibits hepatic glucokinase to reduce glucose-stimulated secretion
E) It activates somatostatin receptors on the beta cell to halt secretion
ANSWER: B
Rationale:
Diazoxide opens (activates) ATP-sensitive potassium (KATP) channels in beta cells; the resulting potassium efflux hyperpolarizes the membrane, keeps voltage-gated calcium channels closed, and suppresses calcium-triggered insulin exocytosis.
Option A: Option A inverts the action: blocking these channels would depolarize the cell and promote insulin release.
Option C: Option C is incorrect: diazoxide does not act on vesicle docking proteins.
Option D: Option D is incorrect: it does not work through glucokinase inhibition.
Option E: Option E is incorrect: KATP-channel opening, not somatostatin-receptor agonism, is its mechanism.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient. After two weeks on diazoxide her hypoglycemia is controlled, but she develops dependent edema and a 3-kg weight gain. Which statement correctly characterizes this finding and its management?
A) It is an allergic reaction requiring immediate permanent discontinuation of diazoxide
B) It reflects hypoalbuminemia best treated with albumin infusions
C) It indicates new heart failure requiring a loop diuretic and a beta-blocker
D) It is the expected sodium and fluid retention caused by diazoxide, commonly managed by co-prescribing a thiazide diuretic such as hydrochlorothiazide
E) It reflects diazoxide-induced hypothyroidism requiring levothyroxine
ANSWER: D
Rationale:
Diazoxide characteristically causes sodium and fluid retention, producing edema and weight gain; this is an expected effect commonly managed by co-prescribing a thiazide diuretic such as hydrochlorothiazide (whose mild hyperglycemic effect is also complementary in this setting).
Option A: Option A is incorrect: this is an expected pharmacologic effect, not an allergy mandating discontinuation.
Option B: Option B is incorrect: the mechanism is sodium and fluid retention, not hypoalbuminemia.
Option C: Option C is incorrect: it reflects drug-induced fluid retention rather than new heart failure.
Option E: Option E is incorrect: the edema is not due to hypothyroidism.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. A consultant asks why a somatostatin analogue was not chosen instead of diazoxide. Which explanation is most accurate for insulinoma specifically?
A) Insulinomas commonly express SSTR3 and SSTR5 without high SSTR2 density, making the response less reliable, and by suppressing counter-regulatory glucagon a somatostatin analogue can paradoxically worsen hypoglycemia, so it is used only with careful glucose monitoring
B) Insulinomas overexpress SSTR2 so intensely that a somatostatin analogue causes uncontrollable hyperglycemia in every patient
C) Insulinomas lack all somatostatin receptors, so a somatostatin analogue is pharmacologically inert
D) A somatostatin analogue stimulates insulin release in insulinoma, directly worsening hypoglycemia, and must never be combined with glucose monitoring
E) The only barrier is the cost and monthly dosing of a somatostatin analogue, with no pharmacological concern
ANSWER: A
Rationale:
Insulinomas frequently express SSTR3 and SSTR5 without high SSTR2 density, so the secretory-inhibitory response to a somatostatin analogue is less reliable than in VIPoma or glucagonoma; moreover, by suppressing counter-regulatory glucagon, these agents can paradoxically deepen hypoglycemia, so they are used only under careful glucose monitoring—making diazoxide the more dependable choice.
Option B: Option B is incorrect: insulinomas often lack high SSTR2 density, the opposite of overexpression.
Option C: Option C overstates the point: they express some somatostatin receptors, just a less favorable subtype profile.
Option D: Option D is incorrect: somatostatin analogues suppress rather than stimulate secretion, and monitoring is exactly what is required.
Option E: Option E is incorrect: the limitation is pharmacological, not merely logistical.
17. [CASE 5 — QUESTION 1]
A 26-year-old woman with anorexia nervosa (BMI 12.5 kg/m2) has had negligible intake for two weeks. Baseline phosphate, potassium, and magnesium are at the low end of normal. As enteral feeding is planned, which electrolyte abnormality is the hallmark danger of refeeding, and what does it cause?
A) Hyperkalemia, causing peaked T waves and cardiac arrest
B) Hypernatremia, causing osmotic demyelination
C) Hypophosphatemia, which impairs ATP production and 2,3-diphosphoglycerate and can cause rhabdomyolysis, respiratory muscle failure, hemolysis, and cardiac arrhythmias
D) Hypercalcemia, causing nephrolithiasis and confusion
E) Hypermagnesemia, causing areflexia and respiratory depression
ANSWER: C
Rationale:
Hypophosphatemia is the hallmark and most dangerous element of refeeding syndrome. Insulin-driven anabolism after carbohydrate reintroduction shifts phosphate into cells; severe hypophosphatemia impairs ATP production and 2,3-diphosphoglycerate, causing rhabdomyolysis, respiratory muscle failure, hemolysis, and arrhythmias.
Option A: Option A inverts the direction: insulin drives potassium into cells, producing hypokalemia.
Option B: Option B is incorrect: refeeding does not characteristically cause hypernatremia.
Option D: Option D is incorrect: hypercalcemia is not a defining refeeding feature.
Option E: Option E inverts the direction: refeeding produces hypomagnesemia from intracellular shift, not hypermagnesemia.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient. Before the first feed, which vitamin must be administered to prevent a specific neurological complication, and why?
A) Vitamin D, to prevent hypocalcemic seizures during refeeding
B) Folate, to prevent subacute combined degeneration during refeeding
C) Vitamin K, to prevent intracranial hemorrhage during repletion
D) Vitamin B12, to prevent a peripheral neuropathy precipitated by glucose loading
E) Thiamine, because carbohydrate refeeding sharply increases thiamine demand and can precipitate Wernicke encephalopathy in a depleted patient
ANSWER: E
Rationale:
Thiamine (200–300 mg IV daily for the first few days) must be given before or alongside refeeding because carbohydrate reintroduction sharply increases demand for thiamine as a cofactor in glucose metabolism; in a depleted patient this can precipitate Wernicke encephalopathy.
Option A: Option A is incorrect: hypocalcemic seizures are not the characteristic refeeding complication prevented by a vitamin.
Option B: Option B is incorrect: subacute combined degeneration is a B12-deficiency entity, not folate, and not a refeeding-specific risk.
Option C: Option C is incorrect: vitamin K addresses coagulopathy, not this neurological risk.
Option D: Option D is incorrect: B12 is not the vitamin given to prevent a refeeding neurological complication.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient. Feeding is started at 10 kcal/kg/day. On day 2 her phosphate falls from 1.0 to 0.5 mmol/L with mildly low potassium and magnesium; she remains asymptomatic. What is the most appropriate management?
A) Rapidly advance to full calories now that feeding has been tolerated
B) Hold caloric advancement, aggressively replete phosphate, potassium, and magnesium, continue thiamine, and resume cautious advancement only once electrolytes stabilize
C) Stop all nutrition indefinitely and discharge on an oral diet
D) Switch to parenteral nutrition at full calories to bypass the electrolyte shifts
E) Add a loop diuretic and continue advancing calories
ANSWER: B
Rationale:
A falling phosphate with low potassium and magnesium on early refeeding signals evolving refeeding syndrome driven by the insulin-mediated intracellular shift. The correct response is to hold caloric advancement, aggressively replete phosphate, potassium, and magnesium, continue thiamine, and resume slow advancement only once electrolytes stabilize, with continued twice-daily monitoring.
Option A: Option A is incorrect: advancing calories now would deepen the dangerous shift.
Option C: Option C is incorrect: nutrition is slowed and electrolytes repleted, not abandoned.
Option D: Option D is incorrect: the parenteral route does not prevent the insulin-driven shifts, and full calories would worsen them.
Option E: Option E is incorrect: a loop diuretic does not address the depletion, and continuing to advance calories is unsafe.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient. As she stabilizes, the team formalizes her refeeding plan. Which approach correctly integrates the core elements of safe refeeding?
A) Start at full estimated calories and check electrolytes weekly, giving thiamine only if symptoms appear
B) Withhold nutrition until phosphate, potassium, and magnesium are supranormal, then start at full calories without thiamine
C) Use parenteral nutrition at full calories because the intravenous route bypasses the shifts
D) Correct electrolytes to safe levels first, start at no more than about 10 kcal/kg/day, advance by roughly a third every two days while monitoring potassium, magnesium, and phosphate, and supplement thiamine
E) Feed orally at full calories with a prophylactic loop diuretic, deferring electrolyte monitoring to day 3
ANSWER: D
Rationale:
Safe refeeding integrates correcting electrolytes to safe levels before feeding, initiating at no more than about 10 kcal/kg/day with cautious advancement (roughly a third every two days) while monitoring potassium, magnesium, and phosphate, and supplementing thiamine.
Option A: Option A is incorrect: full-calorie initiation with delayed monitoring and reactive thiamine is exactly what precipitates refeeding syndrome.
Option B: Option B is incorrect: electrolytes are corrected to safe (not supranormal) levels and thiamine is required.
Option C: Option C is incorrect: the parenteral route does not prevent the shifts, and full calories are unsafe.
Option E: Option E is incorrect: full-calorie oral feeding with a diuretic and deferred monitoring does not address caloric-rate and electrolyte management.
21. [CASE 6 — QUESTION 1]
A 41-year-old man has short bowel syndrome after extensive resection for mesenteric ischemia, leaving minimal residual absorptive surface. He tolerates a polymeric enteral formula poorly. Which enteral formula category is most appropriate, and why?
A) An elemental formula of free amino acids with fat largely as medium-chain triglycerides, because predigested nutrients and micelle-independent fat absorption require the least digestive and absorptive capacity
B) A fiber-enriched standard formula, because fiber increases the absorptive surface available
C) A blenderized whole-food formula, because natural food is better tolerated in short bowel
D) An immune-modulating formula enriched with arginine and glutamine, because pharmaconutrition is proven superior in short bowel syndrome
E) A renal-disease formula, because reducing phosphate and potassium improves nutrient uptake
ANSWER: A
Rationale:
With minimal residual absorptive surface, the appropriate formula demands the least digestive and absorptive work: an elemental formula provides free amino acids and fat largely as medium-chain triglycerides, which are absorbed without micelle formation, so predigested nutrients can be taken up despite limited surface area.
Option B: Option B is incorrect: fiber does not increase absorptive surface area.
Option C: Option C is incorrect: whole-food formulas require full digestive capacity the short bowel lacks.
Option D: Option D is incorrect: immune-modulating pharmaconutrition formulas show heterogeneous or null results and are not established as superior in short bowel syndrome.
Option E: Option E is incorrect: a renal formula adjusts electrolytes for kidney disease and does not address the absorptive limitation.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient. He requires supplemental home parenteral nutrition with a soybean-oil lipid emulsion. After 7 months he develops a rising direct bilirubin and alkaline phosphatase with no biliary obstruction, consistent with PN-associated liver disease. Which change is best supported?
A) Increase the soybean-oil lipid dose to deliver more essential fatty acids
B) Discontinue all lipid permanently and replace the calories with dextrose indefinitely
C) Switch to a fish-oil-containing mixed-oil lipid emulsion, whose anti-inflammatory n-3 fatty acids reduce PN-associated liver disease and can reverse cholestasis
D) Add an oral bile acid sequestrant and continue the soybean-oil emulsion unchanged
E) Stop monitoring liver tests, since PN-associated liver disease is irreversible
ANSWER: C
Rationale:
This is PN-associated liver disease (PNALD) on an n-6-rich soybean-oil emulsion. Switching to a fish-oil-containing mixed-oil emulsion supplies anti-inflammatory n-3 fatty acids, which reduce PNALD incidence and can reverse established cholestasis.
Option A: Option A is incorrect: increasing the n-6-rich emulsion is expected to worsen hepatic injury.
Option B: Option B is incorrect: permanent lipid elimination risks essential fatty acid deficiency and is not supported.
Option D: Option D is incorrect: continuing the implicated emulsion unchanged does not address the lipid composition driving PNALD, and a sequestrant is not the established remedy.
Option E: Option E is incorrect: PNALD warrants active intervention and continued monitoring, not abandonment.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient. His resection included the terminal ileum, and he has been on prolonged parenteral nutrition. Which statement best matches his anticipated micronutrient deficiencies to their mechanisms?
A) He is at risk only for iron deficiency, because all micronutrients except iron are absorbed in the colon
B) He is at risk for vitamin B12 deficiency because terminal ileal uptake (and intrinsic-factor-dependent absorption) is lost, and for selenium deficiency, which in prolonged parenteral nutrition can cause cardiomyopathy and skeletal myopathy
C) He is at risk for no deficiencies because parenteral nutrition delivers all nutrients intravenously and bypasses absorption entirely, requiring no monitoring
D) He is at risk for vitamin B12 deficiency because B12 is absorbed in the duodenum, which is now bypassed
E) He is at risk for fat-soluble vitamin toxicity from the lipid emulsion rather than any deficiency
ANSWER: B
Rationale:
Loss of the terminal ileum removes the cubilin-receptor uptake site for intrinsic-factor-bound vitamin B12, predisposing to B12 deficiency; prolonged parenteral nutrition (and severe malabsorption) also predisposes to selenium deficiency, which can cause cardiomyopathy and skeletal myopathy. Both require monitoring and targeted supplementation.
Option A: Option A is incorrect: the colon does not absorb most micronutrients, and the risk is broader than iron alone.
Option C: Option C is incorrect: parenteral formulations require careful trace-element and vitamin provision and monitoring; deficiencies (such as selenium) occur precisely in this setting.
Option D: Option D is incorrect: B12 is absorbed in the terminal ileum, not the duodenum.
Option E: Option E is incorrect: the concern is deficiency from malabsorption and PN, not fat-soluble vitamin toxicity.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient. The team wishes to minimize further hepatic injury and optimize his parenteral regimen. Which statement best integrates appropriate parenteral nutrition management?
A) Maximize dextrose calories well above energy needs to ensure positive balance, since overfeeding is protective for the liver
B) Provide all calories as lipid to spare the liver from dextrose, regardless of essential fatty acid balance
C) Eliminate trace elements and vitamins to reduce the metabolic burden on the liver
D) Target appropriate energy (about 20–25 kcal/kg/day) and protein (about 1.2–2.0 g/kg/day), avoid overfeeding, preserve some enteral stimulation when possible since absent enteral intake contributes to PN-associated liver disease, and continue trace-element, vitamin, and liver-test monitoring
E) Discontinue all monitoring and fix the macronutrient prescription permanently, since stable patients need no further adjustment
ANSWER: D
Rationale:
Sound parenteral nutrition management targets appropriate energy (about 20–25 kcal/kg/day) and protein (about 1.2–2.0 g/kg/day), avoids overfeeding, preserves enteral stimulation when feasible (absence of enteral intake contributes to PN-associated liver disease), and maintains trace-element, vitamin, and liver-test monitoring.
Option A: Option A is incorrect: overfeeding, especially excess dextrose, worsens hepatic steatosis and injury.
Option B: Option B is incorrect: providing all calories as lipid is not appropriate and ignores balanced macronutrient and essential fatty acid needs.
Option C: Option C is incorrect: removing trace elements and vitamins causes deficiencies (such as selenium) rather than protecting the liver.
Option E: Option E is incorrect: parenteral nutrition requires ongoing monitoring and adjustment, not a fixed permanent prescription.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.